Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Lifting the Mutant Influenza Research Moratorium

by Global Biodefense Staff
June 27, 2012

Several dozen of the world’s leading influenza scientists agreed at the beginning of the year to voluntarily honor a moratorium on research of flu mutations that fall under the Dual Use Research of Concern (DURC) umbrella.

During implementation of the hold, experts agreed the moratorium would only be lifted once funding entities and regulators had determined the biosecurity conditions that would allow such research to be conducted with reasonable guarantees of safety.

Flu researchers will soon be able to argue that those conditions have been met, according to the journal Nature. “We have heard from several researchers that they would like to lift the moratorium sooner rather than later,” says Ron Fouchier, one of its signatories and the lead author on a mutant bird flu manuscript which has been at the epicenter of recent DURC debate. (Read Controversial Fouchier Paper Finally Published).

Next month, the World Health Organization (WHO) will unveil non-binding biosafety and biosecurity guidelines for mutant-influenza research. Over the following months, national regulatory authorities worldwide are expected to produce their own biosafety rules.

The United States government is the largest funder of this type of flu research. Amidst the Fouchier controversy, a new Federal Policy on Dual Use Research of Concern was released in March. Efforts to further develop DURC policies have been happening across government agencies, and the Intra-governmental Select Agents and Toxins Technical Advisory Committee is expected to issue its own biosafety rules soon. Additionally, a more detailed plan for local institutional oversight of DURC is set to be released for public comment in the coming weeks.

Supporters of the moratorium point out that publicizing and expanding some research examining increased pathogenicity and transmission of flu viruses would probably accelerate similar mutant viruses being created in dozens more labs worldwide — some of which may lack adequate biosafety standards. This could multiply the risk of an accidental release of a pathogen capable of sparking a pandemic.

Others argue such research is vital to protecting public health. By better understanding how certain genetic mutations can create the conditions for a pandemic, surveillance and early warning efforts could be improved.

Read more on this topic at Nature.

Tags: BiosafetyDual Use Research of Concern (DURC)Influenza

Related Posts

Liverpool Synthetic Biology Lab Backed By 2M Award
Policy + Initiatives

Political Interference: White House Launches Framework to Protect Scientific Integrity

January 13, 2023
DARPA Pursues Advanced Threat-Detection for Crop Defense
Biosecurity

DARPA Pursues Advanced Threat-Detection for Crop Defense

January 3, 2023
Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
Health Security

Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.

December 7, 2022
Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.
Policy + Initiatives

Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.

December 7, 2022
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC